Investors aboard this roller-coaster stock aren't sure they're having fun yet.
NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you...
A deep pipeline will lead to new drug approvals. AbbVie has a good chance of replacing Humira's revenues during the next couple of years. AbbVie provides a comp
This week FDA granted approval for a new indication of Merck’s (NYSE:MRK) cancer PD-1 inhibitor, Keytruda and gave priority review to label expansion applications filed by...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Sell||Strong Buy||Strong Buy||Strong Buy||Strong Sell|
|Summary||Neutral||Strong Buy||Strong Buy||Strong Buy||Neutral|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Inside Down||15||Current|
|Upside Gap Three Methods||30||Current|
|Three Outside Up||1D||Current|
|Three Outside Up||1W||Current|
|Falling Three Methods||1M||1||Oct 18|
|Bullish Engulfing||1W||1||Nov 04, 2018|
|Bullish Engulfing||1D||1||Nov 15, 2018|
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).Read More
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.